TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33892154
Drug: Eurythmy therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eurythmy therapy
Study: 35654467
Drug: Hypotension Prediction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotension Prediction Index (HPI) based treatment protocol
Study: 34289889
Drug: Hemostatic agent
Normalized name: Hemostatic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemostatic agent
Study: 38519416
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (Control)
Study: 33095509
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg of albuterol
Study: 33095509
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of albuterol
Study: 35364589
Drug: Clazosentan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazosentan (10 mg/hr)
Study: 35434578
Drug: 25 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 µg RBD vaccine (long schedule)
Study: 35434578
Drug: 50 µg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µg RBD vaccine (long schedule)
Study: 35434578
Drug: 25 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 µg RBD vaccine (phase 2)
Study: 35434578
Drug: 50 µg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µg RBD vaccine (phase 2)
Study: 33342530
Drug: Additional monthly
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional monthly SNAP benefits ranging from $1 to $122
Study: 38599715
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg daily
Study: 35779558
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg once daily for 14 days
Study: 34759112
Drug: Docosahexaenoic acid-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docosahexaenoic acid-enriched milk beverage (297 mg docosahexaenoic acid and 137 mg eicosapentaenoic acid)
Study: 32708893
Drug: PE‐5 (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: PE‐5 (75 g glucose ingested 5 min after exercise)
Study: 32708893
Drug: PE‐30 (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: PE‐30 (75 g glucose ingested 30 min after exercise)
Study: 32708893
Drug: Control (Con
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Con - 75 g glucose without exercise)
Study: 34162374
Drug: Sequential MV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential MV (n = 24)
Study: 33454124
Drug: Henagliflozin (2.5-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Henagliflozin (2.5-200 mg single ascending dose)
Study: 33454124
Drug: Henagliflozin (1.25-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Henagliflozin (1.25-100 mg multiple ascending dose for 10 days)
Study: 33475251
Drug: JNJ‐64565111 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐64565111 5.0 mg
Study: 33475251
Drug: JNJ‐64565111 10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐64565111 10.0 mg
Study: 35782634
Drug: Animal-Assisted Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal-Assisted Therapy (AAT) - 8 sessions
Study: 32978352
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution
Study: 33372103
Drug: Rifaximin 550
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 550 mg two times per day and lactulose 25 mL two times per day
Study: 33372103
Drug: Placebo 550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 550 mg two times per day and lactulose 25 mL two times per day
Study: 33877856
Drug: Belumosudil 200
Normalized name: belumosudil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belumosudil 200 mg twice daily
Study: 37291651
Drug: Dexmedetomidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 0.5 μg/kg
Study: 34114980
Drug: Acupoint injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint injection combined with pelvic floor rehabilitation
Study: 36620770
Drug: High-dose atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose atorvastatin (80 mg/day)
Study: 35789217
Drug: Glycerol throat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol throat spray containing cold-adapted cod trypsin (GCTS), administered six times daily at first sign of a common cold
Study: 35789217
Drug: Glycerol throat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol throat spray containing cold-adapted cod trypsin (GCTS)
Study: 32771299
Drug: Stress balls
Normalized name: Halls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress balls during treatment (Group 1)
Study: 37477105
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m²
Study: 37707817
Drug: Standard-dose quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose quadrivalent influenza vaccine
Study: 32879630
Drug: Households with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Households with latrines constructed inside the household compound
Study: 33887147
Drug: Decrease of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decrease of 0.1 mmol/L serum calcium
Study: 35695616
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment
Study: 34453262
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.025% formulation 5
Study: 34453262
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05% cream (Control)
Study: 34057543
Drug: Riboflavin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin (400 mg)
Study: 36178534
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO) therapy (100% oxygen, 240 kPa)
Study: 34893432
Drug: Propofol (1.25×
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.25× minimum infusion rate)
Study: 34893432
Drug: Alfaxalone (1.25×
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone (1.25× minimum infusion rate)
Study: 36200523
Drug: Diammonium glycyrrhizinate
Normalized name: glycyrrhizinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diammonium glycyrrhizinate (DG) 150 mg three times a day combined with clarithromycin 250 mg once a day and isotretinoin 10 mg once every 2 days
Study: 36200523
Drug: Clarithromycin 500 mg
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 500 mg once a day and isotretinoin 10 mg once a day
Study: 36200523
Drug: Clarithromycin 250 mg
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 250 mg once a day and isotretinoin 10 mg once every 2 days combined with DG 150 mg three times a day
Study: 32337917
Drug: Lidocaine (1.5%)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine (1.5%) and dexmedetomidine (0.5 μg/kg)
Study: 32337917
Drug: Lidocaine (1.5%)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine (1.5%) adjusted to 35 cc with normal saline (Control)
Study: 37286215
Drug: MMR vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR vaccine
Study: 33143064
Drug: Active Video
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Video Games (AVGs) intervention, played twice a week for eight weeks.
Study: 33764805
Drug: CC-486 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 (300 mg)
Study: 32304218
Drug: Intensive induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive induction followed by myeloablative chemotherapy and autologous hematopoietic cell rescue (AuHCR)
Study: 33135179
Drug: Intra-oral camera
Normalized name: Calmera Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-oral camera and/or social work consultation
Study: 33135179
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (intra-oral camera and social work consultation)
Study: 33378609
Drug: mRNA-1273 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 (100 µg)
Study: 32815805
Drug: Locked plating
Normalized name: platinic chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locked plating followed by intraoperatively performed glenohumeral joint lavage (group L, n = 31)
Study: 38592002
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy
Study: 32658250
Drug: TAK-003 (tetravalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-003 (tetravalent dengue vaccine candidate), 2 doses, administered 90 days apart (in part 1)
Study: 32658250
Drug: TAK-003 (tetravalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-003 (tetravalent dengue vaccine candidate)
Study: 35039189
Drug: modified constraint‐induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified constraint‐induced movement therapy (mCIMT)
Study: 34151824
Drug: CS- group
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS- group (same solution as CS+ but without dexamethasone palmitate)
Study: 38581842
Drug: Insulin alone
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin alone
Study: 36224110
Drug: Dietary supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplements (multivitamins, minerals, and omega-3 fatty acids)
Study: 32961589
Drug: Conventional Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Care (CC) protocol
Study: 32921155
Drug: Injection dexamethasone
Normalized name: dexamethasone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection dexamethasone with oral glycerol (group I)
Study: 38261469
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (control)
Study: 35869939
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) with MTZ (400 mg) and AMX (500 mg) three times a day for 14 days
Study: 35262910
Drug: Caplacizumab treatment
Normalized name: caplacizumab
DrugBank: Caplacizumab (DB06081)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Caplacizumab treatment
Study: 33053245
Drug: Shock Wave
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shock Wave Therapy associated with Aerobic Exercise Program
Study: 34052826
Drug: Conventional cane
Normalized name: Cane sugar
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional cane gait training (CC group)
Study: 34987147
Drug: Antibiotic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic administration (broad-spectrum antibiotics)
Study: 34987147
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic administration (antibiotic-naïve)
Study: 39415181
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy
Study: 34911566
Drug: C‐Mill therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: C‐Mill therapy (treadmill-based therapy using gait‐dependent augmented reality)
Study: 34911566
Drug: C‐Mill therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: C‐Mill therapy
Study: 36367144
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc for 15 days
Study: 35112504
Drug: Once-weekly subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly subcutaneous dulaglutide 0.75 mg
Study: 32407947
Drug: Intralymphatic immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralymphatic immunotherapy with allergenic extract
Study: 35710253
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (three times a day for 4 weeks)
Study: 32621736
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose water (10 g of glucose in 100 ml of warm water, 5 ml/kg) 1 hour before surgery
Study: 32621736
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose water (10 g of glucose in 100 ml of warm water, 5 ml/kg) 2 hours before surgery
Study: 35396282
Drug: Medical Treatment
Normalized name: Medical air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Treatment (MT)
Study: 36564877
Drug: Regular soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular soy formula intake (≥14 days per month and ≥1350 ml per month)
Study: 32195640
Drug: ILIB-100 mW, 660 ± 10 nm,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ILIB-100 mW, 660 ± 10 nm, 30 applications in total, divided into 3 stages of 10 applications, 30 min each, daily, with a 20‐day interval between each stage
Study: 32195640
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - conventional treatment
Study: 35639946
Drug: Subcutaneous infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous infiltration
Study: 33290875
Drug: Topiramate 50
Normalized name: topiramate 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 50 mg/day + Phentermine 30 mg
Study: 33290875
Drug: Topiramate 100
Normalized name: topiramate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 100 mg/day + Phentermine 15 mg
Study: 33290875
Drug: Topiramate 100
Normalized name: topiramate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 100 mg/day + Phentermine 30 mg
Study: 39639282
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment alone
Study: 33459908
Drug: THSD7A-positive MN
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: THSD7A-positive MN treatment
Study: 35400993
Drug: Programmed intermittent
Normalized name: Program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed intermittent epidural bolus (PIEB) 6 mL·h‐1 of 0.1% ropivacaine
Study: 35400993
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion (CEI) 6 mL·h‐1 of 0.1% ropivacaine
Study: 32358376
Drug: Jiaotai pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiaotai pill (JTP) plus fluoxetine
Study: 36034810
Drug: Jiedu Tongluo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiedu Tongluo Tiaogan Formula (JTTF) + conventional basic treatment
Study: 36034810
Drug: Conventional basic
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional basic treatment
Study: 36907851
Drug: Standard antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotic treatment
Study: 34083113
Drug: Bisoprolol patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol patch therapy
Study: 33000587
Drug: Acupoint therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint therapy combined with spine pinching
Study: 33000587
Drug: Tibolone therapy
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone therapy alone
Study: 33516195
Drug: Geriatric intervention
Normalized name: CATHETER,EXTERNAL CONVEEN #5120 GERIATRIC/PEDIATRIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geriatric intervention and exercise (preoperative CGA, perioperative geriatric in‐ward review, postoperative follow‐up, resistance exercise program twice/week for 2+12 weeks)
Study: 33574145
Drug: Concussion Essentials
Normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concussion Essentials (CE), a multimodal, interdisciplinary delivered, symptom‐tailored treatment involving physiotherapy, psychology, and education, 1 hour per week for up to 8 weeks or until pPCS resolve.
Study: 35674176
Drug: Tablet technology
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet technology and animated videos
Study: 32361934
Drug: High-dose HSYAI
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose HSYAI (70 mg/d)
Study: 32361934
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Dengzhan Xixin Injection, 30 mL/d)
Study: 37478401
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy
Study: 36262968
Drug: Rhus coriaria
Normalized name: Coriaria ruscifolia fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhus coriaria (3 pills daily for 6 days)
Study: 36262968
Drug: Triamcinolone (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolone (oral paste, 3 times a day for 6 days)
Study: 33487031
Drug: LHW-led physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHW-led physical activity counselling program (8-week, once weekly)
Study: 38604213
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy alone
Study: 34798604
Drug: Glibenclamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (5 mg oral for 21 days)
Study: 33450164
Drug: Topical ocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular reproxalap (0.1% ophthalmic solution, 0.5% ophthalmic solution, and 0.5% lipid ophthalmic solution)
Study: 35372979
Drug: Tenapanor 30
Normalized name: tenapanor 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenapanor 30 mg twice daily for 26 weeks
Study: 39536238
Drug: Tirzepatide 10
Normalized name: tirzepatide 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide 10 mg
Study: 35974290
Drug: Alirocumab 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 300 mg every 4 weeks (Q4W)
Study: 35974290
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of statins with alirocumab
Study: 32711519
Drug: Avenanthramide (AVA)
Normalized name: AVENANTHRAMIDES
DrugBank: Avenanthramides (DB14743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avenanthramide (AVA) supplementation (206 mg/kg)
Study: 39486209
Drug: Standard pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmacological treatment
Study: 34677593
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg methylprednisolone
Study: 32199523
Drug: HPD alone
Normalized name: diphenhydramine hydrochloride / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Rindal HPD]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPD alone (1.5 to 2.2 g/kg/day protein)
Study: 32199523
Drug: HPD plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPD plus multistrain probiotic formulation
Study: 32199523
Drug: HPD plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPD plus prebiotic (5.6 g inulin)
Study: 34052081
Drug: Popliteal-sciatic nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Popliteal-sciatic nerve block with 0.5% Bupivacaine (0.25 ml/kg) in Group 2A (ages 7–15)
Study: 34052081
Drug: Local surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local surgical site infiltration with 0.5% Bupivacaine (0.25 ml/kg) in Group 2B (ages 7–15)
Study: 34052081
Drug: Popliteal-sciatic nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Popliteal-sciatic nerve block with 0.5% Bupivacaine (0.25 ml/kg) in Group 1A (ages 1–6)
Study: 39292452
Drug: TAU (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU (treatment as usual)
Study: 38884324
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment
Study: 34474011
Drug: ? blockers
Approvals — FDA: no, EMA: no, PMDA: no
Description: ? blockers in sinus rhythm (n=12,822)
Study: 32768331
Drug: Model group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model group (H2O2 treatment)
Study: 35487141
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo with treatment rationale (OLP+)
Study: 35487141
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo without treatment rationale (OLP-)
Study: 35487141
Drug: No pill
Normalized name: Beano Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pill control (NPC)
Study: 33905555
Drug: Neoadjuvant docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant docetaxel and androgen deprivation therapy
Study: 33905555
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no neoadjuvant therapy)
Study: 34918332
Drug: Resveratrol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol treatment (150 mg/day)
Study: 32942043
Drug: Zibotentan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zibotentan (10 mg daily)
Study: 37409840
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 1 µg kg ‐1 and midazolam 0.12 mg kg ‐1 (DM group)
Study: 37409840
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 1 µg kg ‐1 and ketamine 2 mg kg ‐1 (DK group)
Study: 37409840
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam 0.12 mg kg ‐1 and ketamine 2 mg kg ‐1 (MK group)
Study: 32285126
Drug: Oral cedazuridine/decitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cedazuridine/decitabine (100 mg/35 mg)
Study: 32285126
Drug: IV decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV decitabine (20 mg/m2)
Study: 33581958
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (Group C)
Study: 32359104
Drug: nalmefene 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalmefene 20 mg
Study: 39509231
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure therapy